Oxcarbazepine add-on for drug-resistant focal epilepsy.

The Cochrane Database of Systematic Reviews
Rebecca BresnahanAnthony G Marson

Abstract

Epilepsy is a common neurological disorder. In approximately 30% of epilepsy cases, seizures are uncontrolled by one antiepileptic drug (AED). These people require treatment with a combination of multiple AEDs and are described as having drug-resistant epilepsy. Oxcarbazepine is a keto-analogue of carbamazepine, an established AED, and can be used as an add-on treatment for drug-resistant epilepsy. To assess the efficacy and tolerability of oxcarbazepine as an add-on treatment for people with drug-resistant focal epilepsy. The following databases were searched on 24 September 2018: Cochrane Register of Studies (CRS Web), which includes the Cochrane Epilepsy Group Specialized Register and the Cochrane Central Register of Controlled Trials (CENTRAL); Medline (Ovid) 1946 to 21 September 2018; ClinicalTrials.gov; and the World Health Organization (WHO) International Clinical Trials Registry Platform (ICTRP). Originally, we also searched SCOPUS as a substitute for Embase, but this is no longer necessary, because randomised and quasi-randomised controlled trials in Embase are now included in CENTRAL. Randomised controlled trials with parallel-group or cross-over design, recruiting people of any age with drug-resistant focal epilepsy....Continue Reading

References

Nov 1, 1987·Epilepsia·M A HoutkooperJ A Hulsman
Oct 26, 1999·Epilepsia·M D Privitera
Feb 5, 2000·The New England Journal of Medicine·P Kwan, M J Brodie
Jun 8, 2001·Clinical Therapeutics·M M Kalis, N A Huff
Jun 26, 2001·Seizure : the Journal of the British Epilepsy Association·P E Smith, UNKNOWN UK Oxcarbazepine Advisory Board
Jul 31, 2001·Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology·M La RosaI Grimaldi
Nov 26, 2002·Seminars in Liver Disease·Nancy Leung
Apr 17, 2003·Epilepsy & Behavior : E&B·Ekrem KutluayAhmad Beydoun
Jan 21, 2004·CNS Drugs·Lynne M Bang, Karen L Goa
Oct 22, 2004·Journal of Clinical Pharmacology·Elisabeth ReyOlivier Dulac
May 23, 2007·Clinical Drug Investigation·Gérard Flesch
Oct 22, 2008·International Review of Neurobiology·W Curt LaFranceBruce Hermann
Oct 13, 2009·São Paulo Medical Journal = Revista Paulista De Medicina·Humberto SaconatoAlvaro Nagib Atallah
Oct 17, 2009·Acta Neurologica Scandinavica·A Gil-NagelUNKNOWN BIA-2093-303 Investigators Study Group
Feb 17, 2010·BMJ : British Medical Journal·Jamie J KirkhamPaula R Williamson
Dec 2, 2011·Seizure : the Journal of the British Epilepsy Association·Kathryn BurtonCharles R J C Newton
Apr 16, 2014·Epilepsia·Robert S FisherSamuel Wiebe
Jun 27, 2014·Epilepsia·Gail S BellJosemir W Sander
Apr 4, 2015·The Cochrane Database of Systematic Reviews·Mariangela PanebiancoAnthony G Marson
Mar 20, 2016·British Journal of Anaesthesia·S HeschlM Rigaud
Jun 27, 2019·The Cochrane Database of Systematic Reviews·Siobhan WestRichard Newton

❮ Previous
Next ❯

Related Concepts

Related Feeds

Ataxias

Ataxia is a neurological condition characterized by lack of voluntary coordination of muscle movements including loss of coordination, balance, and speech. Discover the latest research on different types of ataxias here.

Ataxias (MDS)

Ataxia is a neurological condition characterized by lack of voluntary coordination of muscle movements including loss of coordination, balance, and speech. Discover the latest research on ataxia here.

Ataxia

Ataxia is a neurological condition characterized by lack of voluntary coordination of muscle movements including loss of coordination, balance, and speech. Discover the latest research on ataxia here.

Related Papers

The Cochrane Database of Systematic Reviews
Sergio M CastilloS White
The Cochrane Database of Systematic Reviews
Sergio M CastilloArif Shukralla
Arquivos de neuro-psiquiatria
Cristine Mella Baldauf
São Paulo Medical Journal = Revista Paulista De Medicina
Humberto SaconatoAlvaro Nagib Atallah
The Cochrane Database of Systematic Reviews
Muke ZhouFengbo Wu
© 2021 Meta ULC. All rights reserved